 |
|
Genetic Associations With Age-Related Macular Degeneration—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: In response to Dr Damián, we had considered including details of the treatment analysis. However, it would have been necessary to analyze both the interactions with treatment components considered separately (antioxidants vs placebo, zinc vs placebo) as well as in combination (antioxidants with zinc vs placebo). Furthermore, it is important to consider both quantitative interactions (when the direction of the effect is the same in 2 treatment groups, but the magnitude is different) and qualitative interactions (when the direction of the effect is different in different treatment groups). However, these analyses are complex, and we believed that to do justice to the treatment data and not make this article too cumbersome to interpret, the genotype-treatment data would be best presented in a separate publication.
Financial Disclosures: Dr Seddon reports that she is named as an inventor on a patent application (US Patent Application No. 11/066,641, filed by Massachusetts . . . [Full Text of this Article]
Johanna M. Seddon, MD, ScM
jseddon@tufts-nemc.org
Tufts-New England Medical Center
Boston, Massachusetts
Peter J. Francis, MD, PhD;
Michael L. Klein, MD
Casey Eye Institute
Portland, Oregon
Bernard Rosner, PhD
Harvard School of Public Health
Boston, Massachusetts
RELATED LETTER
Genetic Associations With Age-Related Macular Degeneration
Javier Damián
JAMA. 2007;298(14):1637.
EXTRACT
| FULL TEXT
|
